Recent progress in antiviral chemotherapy for respiratory syncytial virus infections.
The recent progress in antiviral chemotherapy against respiratory syncytial virus (RSV) infections was reviewed. RSV infections among high risk individuals, such as premature babies, infants with congenital disease of cardiopulmonary system or immune system and the aged, hospitalised patients with immunosuppressed status are threatened, with high mortality rates and thus need anti-viral chemotherapy. Clinical efficacy of ribavirin and humanized monoclonal antibody (mAb) against RSV infections as well as experimental reports of novel anti-RSV compounds under investigation such as membrane fusion inhibitors were introduced.
Shigeta
S
S
Department of Microbiology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
D000577:Amides; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D001704:Biopolymers / Q000627:therapeutic use; D001952:Bridged-Ring Compounds / Q000627:therapeutic use; D002392:Catechin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015507:Drugs, Investigational; D006571:Heterocyclic Compounds / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008055:Lipids / Q000627:therapeutic use; D019158:N-Acetylneuraminic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009636:Norbornanes; D020319:Oligodeoxyribonucleotides, Antisense / Q000627:therapeutic use; D011720:Pyrazoles; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy*; D012136:Respiratory Syncytial Viruses / Q000472:pathogenicity; D012254:Ribavirin / Q000627:therapeutic use; D012263:Ribonucleosides / Q000627:therapeutic use; D012266:Ribose; D012307:Risk Factors; D013859:Thiocarbamates; D013871:Thiones / Q000627:therapeutic use; D044945:Proanthocyanidins
D000577:Amides; D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; D001704:Biopolymers; D001952:Bridged-Ring Compounds; D002392:Catechin; D015507:Drugs, Investigational; D006571:Heterocyclic Compounds; D016756:Immunoglobulins, Intravenous; D008055:Lipids; D019158:N-Acetylneuraminic Acid; D009636:Norbornanes; D020319:Oligodeoxyribonucleotides, Antisense; D011720:Pyrazoles; D012254:Ribavirin; D012263:Ribonucleosides; D012266:Ribose; D013859:Thiocarbamates; D013871:Thiones; C413863:(2,2-bis(docosyloxymethyl)propyl-5-acetamido-3,5-dideoxy-4,7,8,9-tetra-O-(sodium oxysulfonyl)glycero-alpha-galacto-2-nonulopyranosid)onate; C119093:RD3 0028; C059077:5-ethynyl-1-ribofuranosylimidazole-4-carboxamide; C002997:pyrazofurin; C010052:mizoribine; C046498:tricyclodecane-9-yl-xanthogenate; C546704:crofelemer; D044945:Proanthocyanidins